Abstracts tagged "patient outcomes and treatment"

Abstract Number: 2679 • 2018 ACR/ARHP Annual Meeting
Glucocorticoids Withdrawal in Systemic Lupus Erythematosus: Are Remission and Low Disease Activity Reliable Starting Points for Stopping Therapy? a Real-Life Experience
Viola Signorini, Chiara Tani, Elena Elefante, Chiara Stagnaro, Linda Carli and Marta Mosca, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Glucocorticoids (GC) are a cornerstone of the treatment of Systemic Lupus Erythematosus (SLE); however, a significant organ damage is associated with long-term GC use…
Abstract Number: 2359 • 2013 ACR/ARHP Annual Meeting
Impact Of Etanercept-Methotrexate Treatment Withdrawal On Patient-Reported Outcomes In Patients With Early Rheumatoid Arthritis (PRIZE Trial)
Piotr Wiland¹, B Combe², Oliver FitzGerald³, Hasan Tahir⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Ronald Pedersen⁶, Jack Bukowski⁷, Bonnie Vlahos⁵ and Sameer Kotak⁸, ¹Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ²Hôpital Lapeyronie, Montpellier, France, ³Department of Rheumatology, St.Vincent's University Hospital, Dublin, Ireland, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁸Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Active rheumatoid arthritis (RA) is commonly associated with impairment of physical function and health-related quality of life (QoL), as well as work disability. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].